Maitland, FL (PRWEB) July 03, 2012
On June 7, 2012, the New England Journal of Medicine published an article on the use of vismodegib to treat advanced and metastatic Basal Cell Carcinoma. Among the authors listed was Dr. Solomon, M.D. Ph.D from Ameriderm Research.
Dr. Matt Leavitt, the Founder and CEO of ADCS said, “We are proud of Dr. Solomon’s accomplishment and his continued leadership of Ameriderm Research as a clinical center of excellence for research in dermatology.”
Dr. Solomon, who also holds academic appointments with University of Illinois College of Medicine and University of Central Florida College of Medicine, began a nearly full-time effort to work closely with pharmaceutical companies and universities on innovative drug treatments and has had a steady stream of publications related to such areas as benefit-risk of new drugs, theoretical mechanisms for adverse effects of new drugs, and risk assessments related to in-office dermatological surgery.
In 2008, Dr. Solomon was approached by Genentech regarding an article he had co-authored in the Journal of Surgical Oncology on a patient with metastatic basal cell carcinoma. Following this conversation, Dr Solomon was invited to be an investigator for a phase II clinical trial to test vismodegib (known then as GDC 0449) for the treatment of advanced and metastatic Basal Cell Carcinoma. Dr. Solomon said, “The participation of Ameriderm Research in a trial for a new oncology treatment was a great honor. As a rule, Genentech primarily works with major oncology and academic medical centers.” Dr. Solomon and Ameriderm Research were invited to be one of the initial sites (and for a time the only site on the East Coast) for the expanded access program. This program allowed patients with advanced or metastatic BCC access to the trial drug vismodegib while it was in the process of being approved by the FDA.
Throughout the studies, Dr. Solomon not only recruited a high number of patients but also contributed insights into the theoretical mechanisms of the side effect profile of the drug. Dr. Solomon notes that vismodegib is a breakthrough treatment for advanced and metastatic BCC. Prior to this drug, these patients had no effective treatment. The drug is also part of a new area of medical treatments, which interferes with genetic pathways being sequestered by cancer cells. The drug and how patients respond to the drug will elucidate and help lead to treatments which control the dynamic individualized complex world of cancer cells.
About Advanced Dermatology and Cosmetic Surgery (ADCS)
ADCS, founded in 1990, is the leading dermatology-focused physician practice management company in the United States, with 53 company-affiliated dermatology clinics in Florida and Ohio. ADCS provides clinical, cosmetic, and pathology services. ADCS also provides billing and coding management services for third-party dermatology practices under the Ameriderm trade name.
Paul J. Tuffy – Director of Marketing, ADCS (407) 875-2080 x 1130
1 Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carincoma. New Engl J Med 366: 2171-9, 2012.